Personalized muc1-c induced pluripotent stem cell and dendritic cell based vaccines
AssigneeDana-Farber Cancer Institute, Inc.
InventorDonald Kufe
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to engineered cells expressing heterologous MUC1, MUC1-C or MUC1-C cytoplasmic domain for generating induced pluripotent stem cells that are autologous to a subject.
Claims29
A fibroblast comprising a heterologous nucleic acid sequence encoding MUC1-C operably linked to at least one regulatory sequence, wherein expression of MUC1-C is in an amount that induces pluripotency.
A fibroblast comprising a pluripotency activator consisting of one or more of MUC1, MUC1-C, or MUC1-C cytoplasmic domain.
A fibroblast comprising oligonucleotide means for inducing pluripotency, operably linked to at least one regulatory sequence, wherein expression of the oligonucleotide means for inducing pluripotency is in an amount that induces pluripotency.
A method of making a personalized cancer vaccine comprising:
- (a) obtaining a fibroblast from a subject;
- (b) introducing in the fibroblast, an exogenous nucleic acid sequence encoding MUC1-C operably linked to at least one regulatory sequence;
- (c) expressing MUC1-C in the fibroblast;
- (d) inducing pluripotency of the fibroblast;
- (e) generating an autologous induced pluripotent stem cell from the fibroblast;
- (f) fusing the autologous induced pluripotent stem cell with an autologous dendritic cell to generate a hybrid cell;
- and
- (g) formulating the hybrid cell into a pharmaceutical composition.
Dependencies are inferred from the claim text.